Seres Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Seres Therapeutics, Inc. scores 3/10 on the AskCyborg Cyborg Score (Weak). Highly speculative pre-revenue clinical biotech facing existential cash constraints, pivoting strategy while awaiting Q2 2026 irEC trial readout with potential for turnaround if clinical data succeeds. The company has a market cap of $71.78 million as of February 17, 2026. With cost-reduction measures including 30% workforce reduction, cash runway.
What is Seres Therapeutics, Inc.'s industry? Seres Therapeutics, Inc. (serestherapeutics.com) operates in Biotechnology - Live Biotherapeutics / Microbiome Therapeutics. AskCyborg classifies Seres Therapeutics, Inc. under Biotechnology - Live Biotherapeutics / Microbiome Therapeutics in its company registry.
Seres Therapeutics is a late-clinical-stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The company led the successful devel...
Cyborg Score thesis
Highly speculative pre-revenue clinical biotech facing existential cash constraints, pivoting strategy while awaiting Q2 2026...
Read the full analyst-debate transcript →Get the Latest Seres Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSeres Therapeutics, Inc. Overview
Pro stress-test →Seres Therapeutics is a late-clinical-stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The company led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome biotherapeutic, which was sold to Nestlé Health Science in September 2024.
Strategic Profile
Pro stress-test →Seres has implemented a corporate strategy to advance its live biotherapeutic programs in inflammatory and immune diseases, with a focus on inflammatory bowel disease and immune checkpoint-related enterocolitis. The company has reduced workforce by approximately 30% to extend cash runway through Q3 2026, pausing additional investment in the SER-155 Phase 2 transplant program while prioritizing early-stage inflammatory disease programs.
Competitive Landscape
Pro stress-test →Seres competes in the live biotherapeutics and microbiome therapeutics space with competitors including Fate Therapeutics, Vir Biotechnology, and Altimmune. The company's differentiation comes from its Breakthrough Therapy-designated programs and successful VOWST proof-of-concept, though it faces challenges from larger biotechs with deeper pipelines and superior capitalization.
Industry Context
Seres Therapeutics, Inc. operates in Biotechnology - Live Biotherapeutics / Microbiome Therapeutics.
Key facts
Founded: 2010 · Headquarters: Cambridge, Massachusetts, US · Market cap: $71.78M